This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Radiation Therapy  • Review  • Prognosis/ Outcomes  • Alert me on articles by topic

Susan L. Gearhart, MD

Arch Surg. 2006;141:1253.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

This article discussed the current multimodality approach to the management of rectal cancer and provides a thorough review of each discipline. Today, stage II to III mid to low rectal cancers in the United States receive neoadjuvant chemoradiation (50.4 Gy and continuous infusion 5-FU over 5 to 6 weeks) followed by surgical resection with TME in 6 to 8 weeks. The authors emphasize that the greatest effects of this approach has been a decrease in local recurrence and an increase in sphincter preservation rate. Newer radiotherapeutic, chemotherapeutic, and surgical techniques were included in this review to demonstrate methods of effectively decreasing the morbidity associated with this approach. The discussion is evidence-based and highlights significant contributions to this field within the literature.

Perhaps another important modality in the management of rectal cancer is imaging. Clearly, the beneficial effects of multimodality therapy are stage-specific. Presently, methods of pretreatment . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Induction Chemoradiation for Rectal Cancer
Nancy Han and Susan Galandiuk
Arch Surg. 2006;141(12):1246-1252.
ABSTRACT | FULL TEXT